Literature DB >> 17901541

Studies of anandamide accumulation inhibitors in cerebellar granule neurons: comparison to inhibition of fatty acid amide hydrolase.

Cecilia J Hillard1, Leyu Shi, Venugopal Raju Tuniki, John R Falck, William B Campbell.   

Abstract

The endocannabinoid, N-arachidonylethanolamine (AEA) is accumulated by neurons via a process that has been characterized biochemically but not molecularly. Inhibitors of AEA accumulation have been characterized individually but have not been compared in a single study. Our purpose was to compare the potency of five previously described compounds (AM404, AM1172, VDM11, OMDM-2, and UCM707) both as inhibitors of AEA and N-palmitoylethanolamine (PEA) accumulation by cerebellar granule neurons and as inhibitors of AEA hydrolysis. The compounds all inhibited AEA accumulation; AM404, VDM11 and OMDM-2 with IC(50) values of approximately 5 microM, whereas AM1172 and UCM707 exhibited IC(50) values of 24 and 30 microM, respectively. The compounds also inhibited PEA accumulation; AM404 being the most potent with an IC(50) of 6 microM, whereas the other compounds had IC(50) values in the range of 30-70 microM. All of the compounds potently inhibited AEA hydrolysis by brain membranes; the K(I) values for AM404, VDM11, and UCM707 were less than 1 microM; AM1172 and OMDM-2 exhibited K(I) values of 3 and 10 microM, respectively. The IC(50) values for inhibition of AEA accumulation were compared to the IC(50) values for PEA accumulation and AEA hydrolysis using linear regression. None of the regressions were significant. These data indicate that inhibition of AEA accumulation by neurons is not a result of the inhibition of endocannabinoid hydrolysis and is a process different from the accumulation of PEA. These studies support the hypothesis that the cellular AEA accumulation beyond simple equilibrium between intracellular and extracellular concentrations occurs because AEA binds to an intracellular protein that is not FAAH but that also recognizes the AEA uptake inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17901541      PMCID: PMC2248273          DOI: 10.1007/s12031-007-0045-0

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  21 in total

1.  Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors.

Authors:  M L López-Rodríguez; A Viso; S Ortega-Gutiérrez; I Lastres-Becker; S González; J Fernández-Ruiz; J A Ramos
Journal:  J Med Chem       Date:  2001-12-20       Impact factor: 7.446

2.  Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase.

Authors:  María L López-Rodríguez; Alma Viso; Silvia Ortega-Gutiérrez; Christopher J Fowler; Gunnar Tiger; Eva de Lago; Javier Fernández-Ruiz; José A Ramos
Journal:  J Med Chem       Date:  2003-04-10       Impact factor: 7.446

3.  Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide.

Authors:  T A Day; F Rakhshan; D G Deutsch; E L Barker
Journal:  Mol Pharmacol       Date:  2001-06       Impact factor: 4.436

4.  Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide.

Authors:  S O Jacobsson; C J Fowler
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

5.  Accumulation of anandamide: evidence for cellular diversity.

Authors:  Cecilia J Hillard; Abbas Jarrahian
Journal:  Neuropharmacology       Date:  2005-02-19       Impact factor: 5.250

Review 6.  Cellular accumulation of anandamide: consensus and controversy.

Authors:  Cecilia J Hillard; Abbas Jarrahian
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

7.  Novel selective and metabolically stable inhibitors of anandamide cellular uptake.

Authors:  Giorgio Ortar; Alessia Ligresti; Luciano De Petrocellis; Enrico Morera; Vincenzo Di Marzo
Journal:  Biochem Pharmacol       Date:  2003-05-01       Impact factor: 5.858

8.  Structural determinants for recognition and translocation by the anandamide transporter.

Authors:  D Piomelli; M Beltramo; S Glasnapp; S Y Lin; A Goutopoulos; X Q Xie; A Makriyannis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

9.  Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study.

Authors:  Lidia Ruiz-Llorente; Silvia Ortega-Gutiérrez; Alma Viso; María G Sánchez; Ana M Sánchez; Carlos Fernández; José A Ramos; Cecilia Hillard; Miguel A Lasunción; María L López-Rodríguez; Inés Díaz-Laviada
Journal:  Br J Pharmacol       Date:  2004-01-12       Impact factor: 8.739

10.  Evidence against the presence of an anandamide transporter.

Authors:  Sherrye T Glaser; Nada A Abumrad; Folayan Fatade; Martin Kaczocha; Keith M Studholme; Dale G Deutsch
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-24       Impact factor: 11.205

View more
  12 in total

1.  Anandamide transport inhibition by ARN272 attenuates nausea-induced behaviour in rats, and vomiting in shrews (Suncus murinus).

Authors:  L D O'Brien; C L Limebeer; E M Rock; G Bottegoni; D Piomelli; L A Parker
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

2.  Sapap3 deletion anomalously activates short-term endocannabinoid-mediated synaptic plasticity.

Authors:  Meng Chen; Yehong Wan; Kristen Ade; Jonathan Ting; Guoping Feng; Nicole Calakos
Journal:  J Neurosci       Date:  2011-06-29       Impact factor: 6.167

Review 3.  "Redundancy" of endocannabinoid inactivation: new challenges and opportunities for pain control.

Authors:  Fabiana Piscitelli; Vincenzo Di Marzo
Journal:  ACS Chem Neurosci       Date:  2012-02-27       Impact factor: 4.418

4.  Paradoxical effects of the endocannabinoid uptake inhibitor VDM11 on accumbal neural encoding of reward predictive cues.

Authors:  Erik B Oleson; Joseph F Cheer
Journal:  Synapse       Date:  2012-07-27       Impact factor: 2.562

Review 5.  On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence.

Authors:  Karen Jaqueline Paredes-Ruiz; Karla Chavira-Ramos; Mario Orozco-Morales; Cimen Karasu; Alexey A Tinkov; Michael Aschner; Abel Santamaría; Ana Laura Colín-González
Journal:  Neurotox Res       Date:  2021-11-06       Impact factor: 3.911

6.  Obesity-related dyslipidemia associated with FAAH, independent of insulin response, in multigenerational families of Northern European descent.

Authors:  Yi Zhang; Gabriele E Sonnenberg; Tesfaye Mersha Baye; Jack Littrell; Jennifer Gunnell; Ann DeLaForest; Erin MacKinney; Cecilia J Hillard; Ahmed H Kissebah; Michael Olivier; Russell A Wilke
Journal:  Pharmacogenomics       Date:  2009-12       Impact factor: 2.533

7.  Exploiting nanotechnologies and TRPV1 channels to investigate the putative anandamide membrane transporter.

Authors:  Alessia Ligresti; Luciano De Petrocellis; Dolores Hernán Pérez de la Ossa; Rosario Aberturas; Luigia Cristino; Aniello Schiano Moriello; Andrea Finizio; M Esther Gil; Ana-Isabel Torres; Jesús Molpeceres; Vincenzo Di Marzo
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

8.  Retrograde endocannabinoid signaling at striatal synapses requires a regulated postsynaptic release step.

Authors:  Louise Adermark; David M Lovinger
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-11       Impact factor: 11.205

9.  Inhibition of fatty acid amide hydrolase by kaempferol and related naturally occurring flavonoids.

Authors:  L Thors; M Belghiti; C J Fowler
Journal:  Br J Pharmacol       Date:  2008-06-16       Impact factor: 8.739

10.  A catalytically silent FAAH-1 variant drives anandamide transport in neurons.

Authors:  Jin Fu; Giovanni Bottegoni; Oscar Sasso; Rosalia Bertorelli; Walter Rocchia; Matteo Masetti; Ana Guijarro; Alessio Lodola; Andrea Armirotti; Gianpiero Garau; Tiziano Bandiera; Angelo Reggiani; Marco Mor; Andrea Cavalli; Daniele Piomelli
Journal:  Nat Neurosci       Date:  2011-11-20       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.